Novo Holdings Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
73
- Investments
-
501
- Portfolio
-
134
- Exits
-
205
Novo Holdings General Information
Description
Founded in 1999, Novo Holdings is a venture capital firm based in Copenhagen, Denmark. The firm prefers to invest in biotech, pharma, medtech, bioindustrials, and services.
Contact Information
Investor Status
Actively Seeking New Investments
Trade Association
Danish Venture Capital Association (DAVCA)
National Venture Capital Association (NVCA)
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Other Investor Types
Accelerator/Incubator
Primary Office
- Tuborg Havnevej 19
- 2900 Hellerup
- 2900 Copenhagen
- Denmark
+45 35 00 00 00
Novo Holdings Investments & Acquisitions (501)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Engimmune Therapeutics | 03-May-2022 | Seed Round | 000.00 | Drug Discovery | Generating Revenue | 0ø0000 0ø0000 00000000 00.0 |
| 0000.00 | 29-Mar-2022 | 00000 00000 | 0000 | Other Healthcare Technology Systems | Generating Revenue | 0000 00000 00 |
| 000000 | 28-Mar-2022 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - Phase 1 | 000000 0000000000000 |
| 00000000 | 16-Mar-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 0ø00000 |
| 00000000 | 28-Feb-2022 | 00000 00000 | 0000 | Building Products | Generating Revenue | 000000 00000 00.0 |
| 00000 000000000000 | 22-Feb-2022 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | |
| 000 00000000 | 18-Feb-2022 | 0000000000 | Pharmaceuticals | Profitable | 00000000 0000 | |
| 00000000 000000000 | 16-Feb-2022 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 0000000 000000 00.0 |
| NMD Pharma | 15-Feb-2022 | Later Stage VC | 000.00 | Drug Discovery | Generating Revenue | 000000 0ø00000 |
| Vestaron | 09-Feb-2022 | Later Stage VC | 0000 | Agricultural Chemicals | Generating Revenue | 000000 0000000000000 |
Novo Holdings Exits (205)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Arcellx | 16-Jun-2022 | Public Investment 2nd Offering | 00000 |
| 0000000 | 09-Jun-2022 | 000000000000000000 | 00000 |
| 000000000 00000000 | 31-May-2022 | 000000000000000000 | 00000 |
| 000000 00000000000 | 28-Apr-2022 | 000000 0000000000 | 00000 |
| 0000000 0000000000 | 25-Feb-2022 | 000000000000000000 | 000 |
| 0000000 | 04-Feb-2022 | 000 | 00000 |
| 0000000 000000 | 13-Dec-2021 | 000000000000000000 | 00000 |
| 00 0000000 | 05-Nov-2021 | 000 | 00000 |
| Minerva (Therapeutic Devices) | 26-Oct-2021 | IPO | 0000 |
| Exscientia | 01-Oct-2021 | IPO | 00000 |
Novo Holdings Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Novo Holdings Team (146)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Kasim Kutay | Chief Executive Officer | 0 | 0 | 0 | San Francisco, CA |
| Christoffer Søderberg | Managing Partner & Head of Principal Investments. | 0 | 0 | 0 | Copenhagen, Denmark |
| Morten Beck Jørgensen | Managing Partner, Financial Investments | 0 | 0 | 0 | Copenhagen, Denmark |
| Søren Moller Ph.D | Managing Partner, Novo Seeds | 00 | 0 | 0 | Copenhagen, Denmark |
| Scott Beardsley | Managing Partner, Novo Ventures (US) | San Francisco, CA |
Novo Holdings Co-Investors (465)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| RA Capital Management | 11 | 00 |
|
|
|
| OrbiMed | 0 | 0 | 00 |
|
|
| Rock Springs Capital | 0 | 0 |
|
|
|
| Vivo Capital | 0 | 0 | 0 |
|
|
| Citadel Enterprise Americas | 0 | 0 |
|
|